Obstet Gynecol:依诺肝素联合阿司匹林和单纯阿司匹林在治疗胎盘介导的妊娠并发症中哪个更强?

2016-11-08 haofan MedSci原创

产前预防性使用依诺肝素并不能显著降低采用低剂量肝素治疗在妊娠34周以前诊断重度先兆子痫孕妇由胎盘介导的妊娠并发症。

最近,妇产科领域权威杂志Obstetrics and Gynecology上发表了一篇研究文章,旨在评估从孕周14周开始每天服用依诺肝素加小剂量阿司匹林能否降低妊娠34周前诊断为严重先兆子痫孕妇胎盘介导的并发症。

在这项开放的多中心随机试验中,研究对象的纳入标准为妊娠34周前诊断为严重先兆子痫的孕妇,孕周处于7–13周之间,且为单胎妊娠,并没有计划进行抗凝治疗。符合条件的患者按1:1的比例随机分配到两个组,分别接受每日4000国际单位的依诺肝素加100mg阿司匹林或单独100mg的阿司匹林治疗,该研究通过基于网络的随机系统进行随机化分组。主要复合结局包括孕产妇死亡、围产儿死亡、先兆子痫、小于胎龄儿(体重小于第十位百分位数的患者)以及胎盘早剥。

在2015年2月21日至2009年11月14日期间,共有257名参与者参加该研究。研究之初各组的人口统计学和临床因素相似。其中8名妇女在随机分组后被排除(6名为依诺肝素–阿司匹林组的患者和2名为单纯阿司匹林组的患者),剩下124名参与者分配到接受依诺肝素–阿司匹林治疗组和125名参与者单独接受阿司匹林治疗。5名病人在随访过程中出现失访(2名为依诺肝素–阿司匹林组的患者和3名为单纯接受阿司匹林治疗组的患者)。在两组之间的主要结局并无显著性差异:依诺肝素–阿司匹林组患者发生主要结局事件比例为42/122(34.4%),而单用阿司匹林组患者主要结局事件比例为50/122(41%)(相对风险为0.84,95%可信区间为0.61–1.16,P=0.29),而且两组间的并发症发生率也无统计学差异。


由此可见,在妊娠34周前诊断为重度子痫并接受低剂量阿司匹林治疗的孕妇,产前预防性使用依诺肝素并不显著降低胎盘介导的并发症。

原始出处:


Haddad, Bassam, et al. Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. obstetrics
and gynecology. 2016.November.Volume 128,Number 5,pp.1053-1063(11)

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043929, encodeId=7897204392997, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 26 03:10:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011265, encodeId=49f520112653f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Mar 27 08:10:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984691, encodeId=18631984691e9, content=<a href='/topic/show?id=5b0b4485870' target=_blank style='color:#2F92EE;'>#妊娠并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44858, encryptionId=5b0b4485870, topicName=妊娠并发症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Apr 11 18:10:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757754, encodeId=39621e577544e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jan 16 19:10:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378980, encodeId=f86d13e89807b, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406824, encodeId=215014068244b, content=<a href='/topic/show?id=2aca8365e2c' target=_blank style='color:#2F92EE;'>#胎盘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83657, encryptionId=2aca8365e2c, topicName=胎盘)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTItxfbnwF4Yku2j227me6wl2EGarBoTicR3tHxrMtib5tnyyEEsgxlHkk8JAS4ZjHsEF7PxhBwh1QwQ/132, createdBy=c8162575557, createdName=liuyong2981, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043929, encodeId=7897204392997, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 26 03:10:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011265, encodeId=49f520112653f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Mar 27 08:10:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984691, encodeId=18631984691e9, content=<a href='/topic/show?id=5b0b4485870' target=_blank style='color:#2F92EE;'>#妊娠并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44858, encryptionId=5b0b4485870, topicName=妊娠并发症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Apr 11 18:10:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757754, encodeId=39621e577544e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jan 16 19:10:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378980, encodeId=f86d13e89807b, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406824, encodeId=215014068244b, content=<a href='/topic/show?id=2aca8365e2c' target=_blank style='color:#2F92EE;'>#胎盘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83657, encryptionId=2aca8365e2c, topicName=胎盘)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTItxfbnwF4Yku2j227me6wl2EGarBoTicR3tHxrMtib5tnyyEEsgxlHkk8JAS4ZjHsEF7PxhBwh1QwQ/132, createdBy=c8162575557, createdName=liuyong2981, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
    2017-03-27 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043929, encodeId=7897204392997, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 26 03:10:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011265, encodeId=49f520112653f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Mar 27 08:10:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984691, encodeId=18631984691e9, content=<a href='/topic/show?id=5b0b4485870' target=_blank style='color:#2F92EE;'>#妊娠并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44858, encryptionId=5b0b4485870, topicName=妊娠并发症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Apr 11 18:10:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757754, encodeId=39621e577544e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jan 16 19:10:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378980, encodeId=f86d13e89807b, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406824, encodeId=215014068244b, content=<a href='/topic/show?id=2aca8365e2c' target=_blank style='color:#2F92EE;'>#胎盘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83657, encryptionId=2aca8365e2c, topicName=胎盘)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTItxfbnwF4Yku2j227me6wl2EGarBoTicR3tHxrMtib5tnyyEEsgxlHkk8JAS4ZjHsEF7PxhBwh1QwQ/132, createdBy=c8162575557, createdName=liuyong2981, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043929, encodeId=7897204392997, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 26 03:10:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011265, encodeId=49f520112653f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Mar 27 08:10:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984691, encodeId=18631984691e9, content=<a href='/topic/show?id=5b0b4485870' target=_blank style='color:#2F92EE;'>#妊娠并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44858, encryptionId=5b0b4485870, topicName=妊娠并发症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Apr 11 18:10:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757754, encodeId=39621e577544e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jan 16 19:10:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378980, encodeId=f86d13e89807b, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406824, encodeId=215014068244b, content=<a href='/topic/show?id=2aca8365e2c' target=_blank style='color:#2F92EE;'>#胎盘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83657, encryptionId=2aca8365e2c, topicName=胎盘)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTItxfbnwF4Yku2j227me6wl2EGarBoTicR3tHxrMtib5tnyyEEsgxlHkk8JAS4ZjHsEF7PxhBwh1QwQ/132, createdBy=c8162575557, createdName=liuyong2981, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
    2017-01-16 丁鹏鹏
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043929, encodeId=7897204392997, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 26 03:10:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011265, encodeId=49f520112653f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Mar 27 08:10:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984691, encodeId=18631984691e9, content=<a href='/topic/show?id=5b0b4485870' target=_blank style='color:#2F92EE;'>#妊娠并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44858, encryptionId=5b0b4485870, topicName=妊娠并发症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Apr 11 18:10:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757754, encodeId=39621e577544e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jan 16 19:10:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378980, encodeId=f86d13e89807b, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406824, encodeId=215014068244b, content=<a href='/topic/show?id=2aca8365e2c' target=_blank style='color:#2F92EE;'>#胎盘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83657, encryptionId=2aca8365e2c, topicName=胎盘)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTItxfbnwF4Yku2j227me6wl2EGarBoTicR3tHxrMtib5tnyyEEsgxlHkk8JAS4ZjHsEF7PxhBwh1QwQ/132, createdBy=c8162575557, createdName=liuyong2981, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2043929, encodeId=7897204392997, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Sep 26 03:10:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011265, encodeId=49f520112653f, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Mar 27 08:10:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984691, encodeId=18631984691e9, content=<a href='/topic/show?id=5b0b4485870' target=_blank style='color:#2F92EE;'>#妊娠并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44858, encryptionId=5b0b4485870, topicName=妊娠并发症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Apr 11 18:10:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757754, encodeId=39621e577544e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Jan 16 19:10:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378980, encodeId=f86d13e89807b, content=<a href='/topic/show?id=b0392692831' target=_blank style='color:#2F92EE;'>#依诺肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26928, encryptionId=b0392692831, topicName=依诺肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406824, encodeId=215014068244b, content=<a href='/topic/show?id=2aca8365e2c' target=_blank style='color:#2F92EE;'>#胎盘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83657, encryptionId=2aca8365e2c, topicName=胎盘)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTItxfbnwF4Yku2j227me6wl2EGarBoTicR3tHxrMtib5tnyyEEsgxlHkk8JAS4ZjHsEF7PxhBwh1QwQ/132, createdBy=c8162575557, createdName=liuyong2981, createdTime=Thu Nov 10 14:10:00 CST 2016, time=2016-11-10, status=1, ipAttribution=)]

相关资讯

AHJ: 依诺肝素较普通肝素小出血更多

  加拿大学者的一项研究表明,在溶栓后接受早期或晚期心脏导管操作的ST段抬高心肌梗死(STEMI)高危患者中,依诺肝素与普通肝素疗效相似,但伴有较多的轻度出血。论文发表于《美国心脏杂志》[Am Heart J 2012,163(2):182]。   在TRANSFER-AMI试验中,高危STEMI患者接受溶栓治疗,然后被随机分配接受标准治疗或立即行冠脉造影。此项试验

JTACS:脑部损伤不会增加多发伤患者血管栓塞风险

创伤是深静脉血栓的一个主要危险因素,而脑外伤又被普遍认为会增加深静脉血栓的风险,通常需要常规预防血栓治疗。目前普遍认为多发伤患者无论是否合并脑外伤,具有较高的深静脉栓塞发生风险。但是对于该类患者目前医学界尚不清楚哪些预防方法和措施可以减少深静脉栓塞的发生。哪些合并脑外伤的多发创伤患者发生静脉血栓的机会会不会增加呢? 针对上述疑问,美国佛罗里达州的Evan J. Valle医生进行了一项回顾性研究

JAMA:治疗急性静脉血栓栓塞的新型口服抗凝剂

抗凝剂是包括深静脉血栓形成(DVT) 和肺栓塞(PE)在内的静脉血栓栓塞(VTE)治疗的常见药物选择。 标准治疗 急性静脉血栓栓塞(VTE)患者的初始治疗通常选择肠外抗凝剂,如普通肝素、低分子量肝素、磺达肝癸钠。这类药物的死亡率、静脉血栓栓塞(VTE)复发率、大出血发生率相近。对于大多数患者老说,会在肠外治疗的同时开始口服维生素K拮抗剂华法林,在开始治疗2-3天时维持国际标准化比值

JAMA Surg:依诺肝素预防静脉血栓栓塞

背景:对于外科手术和创伤患者可使用预防剂量依诺肝素预防静脉血栓栓塞(VTE);尽管如此,VTE发病率和死亡率仍很高,并且抗凝血酶Ⅲ或抗Xa因子不足、以及错误的依诺肝素剂量等均会加剧VTE风险。最近的数据表明,标准肝素酶和血栓弹力图(TEG)之间的反应时间(初始纤维蛋白形成时间)差异大于1分钟与VTE风险的降低有关。目的:评估TEG调整的预防剂量依诺肝素对外伤及手术患者VTE风险预防的有效性。方法:

依据ACCP指南行关节置换抗凝会增加出血

为了减少围手术期出血的风险,长期抗凝治疗的患者需要在大手术之前暂停服用抗凝药物。对于其中的一些高风险患者,则建议将长期的抗凝治疗改为普通肝素或低分子肝素等短效药物,其目的在于减少静脉血栓形成,同时避免增加出血的风险。 对于这种接受下肢关节置换的高风险患者的最佳治疗方案,骨科医生和其他专科医生之间一直存有较多的争议。心脏科和内科医生认为,增加抗凝药物的剂量可以明显降低血栓形成的风险,但骨科

ACCP-9骨科手术病人静脉血栓预防指南解读

与以前指南比较,ACCP-9指南成立了由临床专家、决策科学家、系统综述及指南方法学家等组成的专家委员会,且包含1名未参与血栓研究的一线临床医生以保证指南中的建议具有更强的实用性,每位成员均接受ACCP指南方法学培训,每一部分的编辑负责人不再由血栓领域的专家担任,而是没有严重利益冲突的方法学家担当,只有没有任何明显利益冲突的小组成员才能参与推荐意见的决策,严格执行GRADE分级。GRADE体